Astro Pak launches decontamination services subsidiary
Astro Pak Corporation, a US precision cleaning company, has launched a subsidiary, SixLog, to provide on-site biological decontamination services using proprietary iHP (ionised hydrogen peroxide) technology to the life sciences, pharmaceutical and healthcare industries.
SixLog, headquartered in Santa Ana, California, performs decontamination services for equipment, rooms, entire buildings and modes of transport such as ambulances, trains and cruise ships.
The iHP bio decontamination technology was developed for military applications and this will be the first time that it will be used in commercial applications.
The company says technology can be used in open air and, once ionised, it acts like a gas as opposed to a vapour, providing excellent distribution properties and destroying micro-organisms even in hard-to-reach areas.
Steve Feinstein, formerly regional sales manager of a UK manufacturer of hydrogen peroxide vapour generators, has been appointed as SixLog's director of technology.
In addition to the company launch, SixLog has developed a website containing technical papers, presentations, and other downloads on biological decontamination and sterilisation.
You may also like
Hi Tech Manufacturing
A new era in rheometry with Anton Paar’s next-generation MCR series
Read moreBuilding on its industry-leading legacy in rheometry, Anton Paar has unveiled its next generation of modular compact rheometers (MCRs), setting new benchmarks for precision, speed, intelligence, and adaptability in material characterisation
Trending Articles
You may also like
Hi Tech Manufacturing
A new era in rheometry with Anton Paar’s next-generation MCR series
Building on its industry-leading legacy in rheometry, Anton Paar has unveiled its next generation of modular compact rheometers (MCRs), setting new benchmarks for precision, speed, intelligence, and adaptability in material characterisation
Finance
SeaBeLife raises €2 million to advance dual-target cell death therapies
The funding will help fast-track clinical trials for treatments addressing dry age-related macular degeneration and severe acute hepatitis, supporting the company’s innovative approach to blocking two major regulated cell death pathways
Research & Development
Daiichi Sankyo launches third global research institute in San Diego
The company expands its international research footprint with a new San Diego institute, strengthening collaborations in one of the world’s leading life-science hubs and advancing its global drug discovery strategy